Hormone drug may boost healing of cesarean scar defects

NCT ID NCT05206682

Recruiting now Disease control Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares vaginal repair surgery alone versus surgery followed by leuprorelin, a drug that temporarily stops menstruation. The goal is to see if delaying periods helps the scar defect heal better. The trial includes 94 women with cesarean scar defects and adenomyosis who have prolonged bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Leuprorelin
What this could lead to: If it works, this could point toward a better way to treat cesarean scar defects and reduce prolonged menstrual bleeding.
What could go wrong: This is a small, early-stage trial with only 94 participants. The drug may not improve healing, and side effects from leuprorelin are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOMYOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenomyosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CESAREAN SECTION; DEHISCENCE

Contacts and locations

Locations

Shanghai Jiaotong University xinhua hospital
RECRUITING

Shanghai, Shanghai Municipality, 200092, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.